Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 40

Sort by

Sort Order Select

Journal Articles

’Roids without rage via B-cell–targeted ADC?

Rachel E. Rau

Blood (2024) 144 (7): 686–687.

https://doi.org/10.1182/blood.2024025123

Published: 2024

Journal Articles

IFN-γ and CD38 in AML: a T-cell engagement made in heaven?

Adam J. Lamble, Rachel E. Rau

Blood (2024) 143 (16): 1556–1557.

https://doi.org/10.1182/blood.2023023786

Published: 2024

Journal Articles

DNMT3A Regulates Megakaryocyte-Primed HSC Lineage Fate Decisions

Sarah Waldvogel, Rachel E. Rau, Virginia Camacho, Ashlyn G. Laidman, Anna Guzman, Alejandra G Martell, Kellie Machlus, Margaret Goodell

Blood (2023) 142 (Supplement 1): 1303.

https://doi.org/10.1182/blood-2023-187363

Published: 2023

Journal Articles

Efficacy and Safety of Recombinant Erwinia Asparaginase (JZP458) in Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL): Complete Follow-up of the Children's Oncology Group (COG) AALL1931 Study

Luke Maese, Mignon L. Loh, Mi Rim Choi, Tong Lin, Etsuko Aoki, Shirali Agarwal, Vijayalakshmi Chandrasekaran, Yali Liang, Suzette Girgis, Cuiping Chen, Robert Iannone, Lewis B. Silverman, Elizabeth A. Raetz, Rachel E. Rau

Blood (2023) 142 (Supplement 1): 1498.

https://doi.org/10.1182/blood-2023-172577

Published: 2023

Journal Articles

Immunogenicity of Recombinant Erwinia asparaginase (JZP458) for Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL)

Luke Maese, Mignon L. Loh, Mi Rim Choi, Yali Liang, Etsuko Aoki, Shane Roller, Tong Lin, Shirali Agarwal, Vijayalakshmi Chandrasekaran, Robert Iannone, Lewis B. Silverman, Elizabeth A. Raetz, Rachel E. Rau

Blood (2023) 142 (Supplement 1): 5908.

https://doi.org/10.1182/blood-2023-179533

Published: 2023

Journal Articles

Recombinant Erwinia asparaginase (JZP458) in acute lymphoblastic leukemia: results from the phase 2/3 AALL1931 study

Luke Maese, Mignon L. Loh, Mi Rim Choi, Tong Lin, Etsuko Aoki, Michelle Zanette, Shirali Agarwal, Robert Iannone, Jeffrey A. Silverman, Lewis B. Silverman, Elizabeth A. Raetz, Rachel E. Rau

Blood (2023) 141 (7): 704–712.

https://doi.org/10.1182/blood.2022016923

Published: 2023

Includes: Supplemental data

Journal Articles

Efficacy, Safety, and Population Pharmacokinetic Modeling of Intravenous Recombinant Erwinia Asparaginase (JZP458) in Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma: Results from Study AALL1931

Luke Maese, Mignon L. Loh, Mi Rim Choi, Tong Lin, Etsuko Aoki, Shirali Agarwal, Xiaotian Wu, Robert Iannone, Jeffrey A. Silverman, Lewis B. Silverman, Elizabeth A. Raetz, Rachel E. Rau

Blood (2022) 140 (Supplement 1): 8969–8970.

https://doi.org/10.1182/blood-2022-160192

Published: 2022

Journal Articles

Cohesin Gene Haploinsufficiency Does Not Prevent Development of Inv(16) Acute Myeloid Leukemia

Shannon E. Conneely, Jason H. Rogers, Rogelio Aguilar, Kristen J Kurtz, Paul P. Liu, Margaret A. Goodell, Debananda Pati, Rachel E. Rau

Blood (2022) 140 (Supplement 1): 5868–5869.

https://doi.org/10.1182/blood-2022-165368

Published: 2022

Journal Articles

Relocalization of PU.1 Underlies the On- and Off-Tumor Effects of SWI/SNF Blockade in AML

Courtney Chambers, Kristen Kurtz, Andrew Henry Lewis, Katharina Wohlan, Yuen San Chan, Katerina Cermakova, Milan Dejmek, Michal Sala, Rogelio Aguilar, Mario Loeza Cabrera, Radim Nencka, H. Daniel Lacorazza, Rachel E. Rau, H. Courtney Hodges

Blood (2022) 140 (Supplement 1): 2242–2243.

https://doi.org/10.1182/blood-2022-165396

Published: 2022

Journal Articles

Combination of the Kdm-Family Inhibitor, Jib-04, Improves Response to Acute Myeloid Leukemia Cells to Venetoclax

Katharina Wohlan, Dandan Fan, Anna Guzman, Jianzhong Su, Margaret A. Goodell, Rachel E. Rau

Blood (2022) 140 (Supplement 1): 5953–5954.

https://doi.org/10.1182/blood-2022-160199

Published: 2022

Journal Articles

Blinatumomab Associated Seizure Risk in Patients with Down Syndrome and B-Lymphoblastic Leukemia: An Interim Report from Children's Oncology Group (COG) Study AALL1731

Amanda M. Li, Karen R Rabin, John Kairalla, Cindy Wang, Meenakshi Devidas, Olga Militano, Maki Okada, Johann K Hitzler, Anne L Angiolillo, Elizabeth A. Raetz, Mignon L. Loh, Sumit Gupta, Rachel E. Rau

Blood (2021) 138 (Supplement 1): 2304.

https://doi.org/10.1182/blood-2021-148967

Published: 2021

Journal Articles

Initial Results from a Phase 2/3 Study of Recombinant Erwinia Asparaginase (JZP458) in Patients with Acute Lymphoblastic Leukemia (ALL)/Lymphoblastic Lymphoma (LBL) Who Are Allergic/Hypersensitive to E. coli-Derived Asparaginases

Luke Maese, Mignon L. Loh, Tong Lin, Etsuko Aoki, Michelle Zanette, Shirali Agarwal, Jeffrey A. Silverman, Mi Rim Choi, Lewis B. Silverman, Elizabeth A. Raetz, Rachel E. Rau

Blood (2021) 138 (Supplement 1): 2307.

https://doi.org/10.1182/blood-2021-147023

Published: 2021

Journal Articles

A viral cause of APL

Rachel E. Rau

Blood (2021) 138 (18): 1653–1655.

https://doi.org/10.1182/blood.2021013630

Published: 2021

Journal Articles

Effects of Race and Ethnicity on Clinical Features, Tumor Genetics and Outcome in Children with KMT2A Rearranged Acute Myeloid Leukemia

Casey L. McAtee, MD, Joseph Lubega, MBChB, MPH, Michael E. Scheurer, PhD MPH, Rachel E. Rau, MD

Blood (2020) 136 (Supplement 1): 34.

https://doi.org/10.1182/blood-2020-136737

Published: 2020

Journal Articles

Impact of Race/Ethnicity on Pediatric Core Binding Factor AML Outcomes and Response to Gemtuzumab Ozogamicin

Shannon E. Conneely, MD, Casey L. McAtee, MD, Rachel E. Rau, MD

Blood (2020) 136 (Supplement 1): 10–11.

https://doi.org/10.1182/blood-2020-138890

Published: 2020

Journal Articles

SIRPA ssing other xenograft murine models?

Rachel E. Rau

Blood (2020) 135 (19): 1612–1614.

https://doi.org/10.1182/blood.2020005554

Published: 2020

Journal Articles

Targeting Activated Signaling Pathways for the Treatment of IKZF1 -Deleted B Lymphoblastic Leukemia

Rohit Gupta, BA, Jason H. Rogers, MS, Xin Long, PhD, Geraldo Medrano, BS, Jaime M. Reyes, BS, Michele Redell, MD PhD, Zachary T Ball, PhD, Margaret Goodell, PhD, Rachel E. Rau, MD

Blood (2019) 134 (Supplement_1): 3789.

https://doi.org/10.1182/blood-2019-127209

Published: 2019

Journal Articles

A Novel Short Latency, High Penetrance Model of KRAS Mutation-Driven T-Cell Acute Lymphoblastic Leukemia

Jacob J. Junco, PhD, Vincent Ulysses Gant, PhD, Maci S. Terrell, BS, Matthew Benjamin Miller, MD, Chun Shik Park, PhD, Taylor J Chen, BS, H. Daniel Lacorazza, PhD, Margaret Goodell, PhD, Rachel E. Rau, MD, Karen R. Rabin, MD PhD

Blood (2019) 134 (Supplement_1): 3792.

https://doi.org/10.1182/blood-2019-126858

Published: 2019

Journal Articles

Open-Label, Multicenter, Phase 2/3 Study of Recombinant Crisantaspase Produced in Pseudomonas Fluorescens ( RC-P) in Patients with Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL) Following Hypersensitivity to Escherichia coli -Derived Asparaginases

Luke Maese, DO, Rachel E. Rau, MD, Elizabeth A. Raetz, MD, Tong Lin, Jin Zhu, Pil Kim, Reddy Chandula, Sherrie McClung, Julie Gray, Mi Rim Choi, MD, Mignon L. Loh, MD, Peter C. Adamson

Blood (2019) 134 (Supplement_1): 2586.

https://doi.org/10.1182/blood-2019-123710

Published: 2019

Journal Articles

Mosaic DNMT3A Germline Mutation As a Model for Mutant DNMT3A Competitive Advantage in the Blood Lineage

Ayala Tovy, PhD, Hyun Jung Park, PhD, Jaime M. Reyes, BS, Anna Guzman, Rachel E. Rau, MD, Aaron Jeffries, PhD, Mill Jonnathan, PhD, Emma Baple, PhD, Andrew Crosby, MD, Mia Petljak, Henry Lee-Six, PhD, Heng Wang, MD PhD, Xin Baozhong, MD PhD, Mathijs A. Sanders, PhD, Peter J. Campbell, PhD, Michael Stratton, Wei Li, Margaret Goodell, PhD

Blood (2018) 132 (Supplement 1): 173.

https://doi.org/10.1182/blood-2018-173

Published: 2018

NARROW

’Roids without rage via B-cell–targeted ADC?

IFN-γ and CD38 in AML: a T-cell engagement made in heaven?

DNMT3A Regulates Megakaryocyte-Primed HSC Lineage Fate Decisions

Efficacy and Safety of Recombinant Erwinia Asparaginase (JZP458) in Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL): Complete Follow-up of the Children's Oncology Group (COG) AALL1931 Study

Immunogenicity of Recombinant Erwinia asparaginase (JZP458) for Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL)

Recombinant Erwinia asparaginase (JZP458) in acute lymphoblastic leukemia: results from the phase 2/3 AALL1931 study

Efficacy, Safety, and Population Pharmacokinetic Modeling of Intravenous Recombinant Erwinia Asparaginase (JZP458) in Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma: Results from Study AALL1931

Cohesin Gene Haploinsufficiency Does Not Prevent Development of Inv(16) Acute Myeloid Leukemia

Relocalization of PU.1 Underlies the On- and Off-Tumor Effects of SWI/SNF Blockade in AML

Combination of the Kdm-Family Inhibitor, Jib-04, Improves Response to Acute Myeloid Leukemia Cells to Venetoclax

Blinatumomab Associated Seizure Risk in Patients with Down Syndrome and B-Lymphoblastic Leukemia: An Interim Report from Children's Oncology Group (COG) Study AALL1731

Initial Results from a Phase 2/3 Study of Recombinant Erwinia Asparaginase (JZP458) in Patients with Acute Lymphoblastic Leukemia (ALL)/Lymphoblastic Lymphoma (LBL) Who Are Allergic/Hypersensitive to E. coli-Derived Asparaginases

A viral cause of APL

Effects of Race and Ethnicity on Clinical Features, Tumor Genetics and Outcome in Children with KMT2A Rearranged Acute Myeloid Leukemia

Impact of Race/Ethnicity on Pediatric Core Binding Factor AML Outcomes and Response to Gemtuzumab Ozogamicin

SIRPA ssing other xenograft murine models?

Targeting Activated Signaling Pathways for the Treatment of IKZF1 -Deleted B Lymphoblastic Leukemia

A Novel Short Latency, High Penetrance Model of KRAS Mutation-Driven T-Cell Acute Lymphoblastic Leukemia

Open-Label, Multicenter, Phase 2/3 Study of Recombinant Crisantaspase Produced in Pseudomonas Fluorescens ( RC-P) in Patients with Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL) Following Hypersensitivity to Escherichia coli -Derived Asparaginases

Mosaic DNMT3A Germline Mutation As a Model for Mutant DNMT3A Competitive Advantage in the Blood Lineage

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only